Literature DB >> 33826547

Significance of Alpha-inhibin Expression in Pheochromocytomas and Paragangliomas.

Ozgur Mete1, Sara Pakbaz, Antonio M Lerario, Thomas J Giordano, Sylvia L Asa.   

Abstract

Alpha-inhibin expression has been reported in pheochromocytomas and paragangliomas (PPGLs). We analyzed alpha-inhibin immunohistochemistry in 77 PPGLs (37 pheochromocytomas [PCCs] and 40 paragangliomas) and correlated the results with catecholamine profile, tumor size, Ki-67 labeling index, succinate dehydrogenase B subunit and carbonic anhydrase IX (CAIX) staining, and genetic pathogenesis. PPGLs were classified as pseudohypoxic cluster 1 disease with documented VHL mutation or SDHx mutation or biochemical phenotype, whereas NF1-driven and RET-driven PPGLs and those with a mature secretory (adrenergic or mixed adrenergic and noradrenergic) phenotype were classified as cluster 2 disease. The Cancer Genome Atlas data on INHA expression in PPGLs was examined. Alpha-inhibin was positive in 43 PPGLs (56%). Ki-67 labeling indices were 8.07% and 4.43% in inhibin-positive and inhibin-negative PPGLs, respectively (P<0.05). Alpha-inhibin expression did not correlate with tumor size. Alpha-inhibin was expressed in 92% of SDHx-related and 86% of VHL-related PPGLs. CAIX membranous staining was found in 8 of 51 (16%) tumors, including 1 SDHx-related PCC and all 5 VHL-related PCCs. NF1-driven and RET-driven PPGLs were negative for alpha-inhibin and CAIX. Alpha-inhibin was expressed in 77% of PPGLs with a pseudohypoxia signature, and 20% of PPGLs without a pseudohypoxia signature (P<0.05). PPGLs with a mature secretory phenotype were negative for CAIX. The Cancer Genome Atlas data confirmed higher expression of INHA in cluster 1 than in cluster 2 PPGLs. This study identifies alpha-inhibin as a highly sensitive (90.3%) marker for SDHx/VHL-driven pseudohypoxic PPGLs. Although CAIX has low sensitivity, it is the most specific biomarker of VHL-related pathogenesis. While alpha-inhibin cannot replace succinate dehydrogenase B subunit immunohistochemistry for detection of SDHx-related disease, it adds value in prediction of cluster 1 disease. Importantly, these data emphasize that alpha-inhibin is not a specific marker of adrenal cortical differentiation, as it is also expressed in PCCs.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Year:  2021        PMID: 33826547     DOI: 10.1097/PAS.0000000000001715

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  8 in total

Review 1.  Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas.

Authors:  Ozgur Mete; Sylvia L Asa; Anthony J Gill; Noriko Kimura; Ronald R de Krijger; Arthur Tischler
Journal:  Endocr Pathol       Date:  2022-03-13       Impact factor: 3.943

Review 2.  Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms.

Authors:  Guido Rindi; Ozgur Mete; Silvia Uccella; Olca Basturk; Stefano La Rosa; Lodewijk A A Brosens; Shereen Ezzat; Wouter W de Herder; David S Klimstra; Mauro Papotti; Sylvia L Asa
Journal:  Endocr Pathol       Date:  2022-03-16       Impact factor: 3.943

Review 3.  Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Overview of the 2022 WHO Classification of Head and Neck Neuroendocrine Neoplasms.

Authors:  Ozgur Mete; Bruce M Wenig
Journal:  Head Neck Pathol       Date:  2022-03-21

Review 4.  Metastatic Neuroendocrine Neoplasms of Unknown Primary: Clues from Pathology Workup.

Authors:  Carl Christofer Juhlin; Jan Zedenius; Anders Höög
Journal:  Cancers (Basel)       Date:  2022-04-28       Impact factor: 6.575

Review 5.  Pheochromocytomas and Abdominal Paragangliomas: A Practical Guidance.

Authors:  Jan Calissendorff; Carl Christofer Juhlin; Irina Bancos; Henrik Falhammar
Journal:  Cancers (Basel)       Date:  2022-02-12       Impact factor: 6.639

Review 6.  Overview of the 2022 WHO Classification of Adrenal Cortical Tumors.

Authors:  Ozgur Mete; Lori A Erickson; C Christofer Juhlin; Ronald R de Krijger; Hironobu Sasano; Marco Volante; Mauro G Papotti
Journal:  Endocr Pathol       Date:  2022-03-14       Impact factor: 4.056

7.  VHL mosaicism: the added value of multi-tissue analysis.

Authors:  Leslie E Oldfield; Jessica Grzybowski; Sylvie Grenier; Elizabeth Chao; Gregory S Downs; Kirsten M Farncombe; Tracy L Stockley; Ozgur Mete; Raymond H Kim
Journal:  NPJ Genom Med       Date:  2022-03-18       Impact factor: 8.617

8.  Case Report: Giant Paraganglioma of the Skull Base With Two Somatic Mutations in SDHB and PTEN Genes.

Authors:  Ailsa Maria Main; Götz Benndorf; Ulla Feldt-Rasmussen; Kåre Fugleholm; Thomas Kistorp; Anand C Loya; Lars Poulsgaard; Åse Krogh Rasmussen; Maria Rossing; Christine Sølling; Marianne Christina Klose
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-13       Impact factor: 6.055

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.